Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 1

Interventions

Radiosurgery 26Radiotherapy 16Erlotinib Hydrochloride 14Magnetic Resonance Spectroscopy 13Bevacizumab 13Pemetrexed 10Carboplatin 10Gefitinib 9pembrolizumab 8osimertinib 8icotinib 7Temozolomide 7Nivolumab 6Specimen Handling 5Paclitaxel 5Spermine Synthase 4Mental Status and Dementia Tests 4Ipilimumab 4Drug Therapy 4Cisplatin 4atezolizumab 3alectinib 3aflutinib 3Immunotherapy 3Fluorodeoxyglucose F18 3regorafenib 2paclitaxel-Angiopep-2 conjugate 2motexafin gadolinium 2epothilone B 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Pharmacogenomic Variants × Thoracic × Clear all
NCT03520842 2023-08-01

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

Stanford University

Phase 2 Completed
22 enrolled 20 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡